ATE237589T1 - Catecholdiether-derivate verwendbar als pharmazeutische mittel - Google Patents

Catecholdiether-derivate verwendbar als pharmazeutische mittel

Info

Publication number
ATE237589T1
ATE237589T1 AT95923739T AT95923739T ATE237589T1 AT E237589 T1 ATE237589 T1 AT E237589T1 AT 95923739 T AT95923739 T AT 95923739T AT 95923739 T AT95923739 T AT 95923739T AT E237589 T1 ATE237589 T1 AT E237589T1
Authority
AT
Austria
Prior art keywords
pct
pharmaceutical agents
date
pde
tnf
Prior art date
Application number
AT95923739T
Other languages
English (en)
Inventor
Allen J Duplantier
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE237589T1 publication Critical patent/ATE237589T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Dental Preparations (AREA)
AT95923739T 1995-06-07 1995-06-07 Catecholdiether-derivate verwendbar als pharmazeutische mittel ATE237589T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/007208 WO1996040636A1 (en) 1995-06-07 1995-06-07 Catechol diethers derivatives useful as pharmaceutical agents

Publications (1)

Publication Number Publication Date
ATE237589T1 true ATE237589T1 (de) 2003-05-15

Family

ID=22249266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95923739T ATE237589T1 (de) 1995-06-07 1995-06-07 Catecholdiether-derivate verwendbar als pharmazeutische mittel

Country Status (11)

Country Link
US (1) US6028086A (de)
EP (1) EP0869945B1 (de)
JP (1) JP3410104B2 (de)
AT (1) ATE237589T1 (de)
CA (1) CA2223245C (de)
DE (1) DE69530429T2 (de)
DK (1) DK0869945T3 (de)
ES (1) ES2193196T3 (de)
FI (1) FI114468B (de)
PT (1) PT869945E (de)
WO (1) WO1996040636A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9903919D0 (en) * 1999-02-19 1999-04-14 Darwin Discovery Ltd Aminophenols and their therapeutic use
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
CA2402384A1 (en) * 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
KR20040010713A (ko) 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
AU2003277562B2 (en) 2002-11-06 2009-03-26 Aska Pharmaceutical Co., Ltd. Pyrazolonaphthyridine derivative
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
US9463426B2 (en) * 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
WO2007032466A1 (ja) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. 複素環化合物、その製造方法並びに用途
US8604031B2 (en) * 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
EP2196465A1 (de) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea-Derivate als PDE4 Hemmern
EP2226323A1 (de) 2009-02-27 2010-09-08 Almirall, S.A. Neuartige Tetrahydropyrazol[3,4-c]isochinolin-5-amin-Derivate
EP2380890A1 (de) 2010-04-23 2011-10-26 Almirall, S.A. Neue 7,8-Dihydro-1,6-Naphthyridin-5(6H)-on-Derivate als PDE4 Inhibitoren
EP2394998A1 (de) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl Derivate als PDE4 Inhibitoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
GB9315595D0 (en) * 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds

Also Published As

Publication number Publication date
DK0869945T3 (da) 2003-07-14
CA2223245A1 (en) 1996-12-19
ES2193196T3 (es) 2003-11-01
EP0869945A1 (de) 1998-10-14
MX9709869A (es) 1998-03-31
CA2223245C (en) 2002-05-21
JP2001527508A (ja) 2001-12-25
WO1996040636A1 (en) 1996-12-19
PT869945E (pt) 2003-09-30
DE69530429D1 (de) 2003-05-22
FI974442L (fi) 1997-12-05
JP3410104B2 (ja) 2003-05-26
US6028086A (en) 2000-02-22
DE69530429T2 (de) 2003-10-30
FI114468B (fi) 2004-10-29
EP0869945B1 (de) 2003-04-16
FI974442A0 (fi) 1997-12-05

Similar Documents

Publication Publication Date Title
NO971811L (no) Bicykliske tetrahydropyrazolopyridiner og deres anvendelse som legemidler
CA2166721A1 (en) Bicyclic tetrahydro pyrazolopyridines
DK0738270T3 (da) Dihydropyrazolopyrroler
DE69530429D1 (de) Catecholdiether-derivate verwendbar als pharmazeutische mittel
ATE234270T1 (de) Cathecoldiether als selektive pde iv hemmungsmittel
EA200200662A1 (ru) Никотинамидные бензоконденсированные гетероциклические производные, полезные в качестве селективных ингибиторов pde4-изозимов
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
NO980313L (no) N-(aroyl)glysin-hydroksaminsyre-derivater og beslektete forbindelser
ATE284860T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
JP2006503048A5 (de)
FI945555A0 (fi) Substituoituja oksindoleja
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
EA200300621A1 (ru) Биарильные производные никотинамида, полезные в качестве ингибиторов изоферментов pde4
JP2006512293A5 (de)
GEP20033029B (en) Substituted 1,8-Naphthyridin-4(1H)-Ones as Phosphodiesterase 4 Inhibitors
GEP20104973B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
MY116527A (en) Tricyclic 5, 6-dihydro-9h-pyrazolo [3,4,-c]-1,2,4- triazolo [4,3-a] pyridines
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
WO2002089782A3 (en) Dioxanes and uses thereof
ATE389655T1 (de) Pyrimidinderivate
WO1999018099B1 (en) Aryl thiophene derivatives as pde iv inhibitors
JP2003501469A5 (de)
ATE294572T1 (de) Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten
US5753691A (en) Agents for inhibiting the production of IL-1β and the release of TNFα

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0869945

Country of ref document: EP

REN Ceased due to non-payment of the annual fee